Click here to learn more about the Impact Organisation
30 people die from asthma each day. Asthma symptoms are not specific and the diagnosis is heavily dependent on a detailed clinical history with some supporting clinical findings and supportive investigative tests; there is no specific diagnostic test for asthma. It is also common for patients not to present any asthma symptoms at the time of their clinical visit. Without a gold standard test available today, asthma diagnosis is still principally based on a patient’s thorough medical history recorded by experienced clinicians orally instead of clinical evidence. This is a highly subjective approach for young children especially to describe their medical history accurately. The current practice of asthma diagnosis is therefore subjective and requires several repeated follow-up visitations by patients before appropriate medication can be prescribed to patients to control their symptoms. This process can take up to years, endangering a patient’s life from inadequate treatment control plan.
At AEVice Health, we have developed a solution to tackle this problem. Using our proprietary technology, the AEvice device can provide a continuous longitudinal (i.e. over a long duration covering possibly pre-attack, attack and post-attack events) measurement on a patient’s the breathing pattern, duration of wheeze and the intensity of coughs. Most importantly, this device can also be used for young children (and also elderly bed-ridden patients). AEvice device empowers patients to take early intervention and achieve better clinical outcomes, reducing hospital visits and help reduce long-term medical cost. For the first time ever, it also empowers clinicians with objective data to better diagnose their patients faster and tailor a more personalised treatment.